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ABSTRACT 
Objective: The objective of the present study was to evaluate the enhancement in brain uptake of liposomes containing atomoxetine (ATX-Lipo) for 
intranasal delivery in the management of Attention Deficit Hyperactivity Disorder (ADHD).  
Methods: ATX-Lipo and ATX mucoadhesive liposomes (ATX-Muco Lipo) with and without a vasoconstrictor phenylephrine (PHE) were prepared by 
lipid film hydration method and characterized for physicochemical parameters. Biodistribution and pharmacokinetic evaluation of ATX-Lipo in the 
brain and blood of Sprague Dawley rats following intranasal (i. n.) and intravenous (i. v.) administrations were examined using optimized 
technetium-labeled (99m Tc-labeled) atomoxetine formulations. Gamma scintigraphy imaging was performed in Sprague Dawley rats. 
Results: ATX-Lipo and ATX-Muco Lipo were found to be stable with average particle size of 404.35±1.86 nm and 510.50±1.22 nm respectively.99mTc 
tagged ATX-Lipo, ATX-Muco Lipo, ATX+PHE-Muco Lipo and ATX solution were found to be stable and suitable for in vivo studies. On comparing ATX 
concentrations after i. n. administrations of ATX-Lipo, ATX-Muco Lipo and ATX+PHE-Muco Lipo and i. v. administration of ATX-Lipo, brain/blood uptake 
ratios (BBR) at 30 min were found to be 0.161, 1.255, 0.331, and 0.003 respectively. These results revealed effective brain targeting following i. n. 
administration of mucoadhesive ATX liposomes. Higher drug targeting efficiency (% DTE) and direct transport percentage (%DTP) for mucoadhesive 
liposomes indicated considerable brain targeting from ATX-Muco liposomes. Gamma scintigraphy imaging of the rat brain conclusively demonstrated 
the greater extent of transport of atomoxetine by ATX+PHE-Muco Lipo (i. n.), when compared with ATX solution (i. n.) into the rat brain. 
Conclusion: This preliminary investigation demonstrates a considerable extent of transport of ATX into the brain through i. n. ATX+PHE-Muco Lipo, 
which may prove to be a new platform for better management of ADHD. 
Keywords: Intranasal delivery, Brain targeting, Mucoadhesive liposomes, Vasoconstrictor, Radiolabeling, Drug targeting efficiency, Direct transport 
percentage, Gamma scintigraphy. 
© 2016 The Authors. Published by Innovare Academic Sciences Pvt Ltd. This is an open access article under the CC-BY license (http://creativecommons.org/licenses/by/4.0/) 
 
INTRODUCTION 
Attention Deficit Hyperactivity disorder (ADHD) or hyperkinetic 
disorder is one of the most common neurodevelopmental disorders 
affecting approximately 5% of children and adolescents worldwide. 
In approximately 80% of children with ADHD, symptoms may 
persist even in adolescence and continue up to adulthood [1]. 
Children and youths who suffer from ADHD are most likely troubled 
with hyperactivity, impulsivity, distractibility and inattention. Older 
adults most likely suffer from attention difficulties and perhaps 
executive function deficits. ADHD has gained worldwide prevalence 
and the treatment of this neurodevelopmental disorder requires all-
day symptom control and to improve patient compliance especially 
in children by providing flexibility in the onset and duration of action 
of any specific medication regardless of the child’s variable daily 
activities or needs [2]. Pharmacological and behavioural interventions 
have been explored for the treatment of ADHD. Pharmacotherapy 
mainly with psychostimulants like methylphenidate and 
antidepressants remains the standard practice for ADHD management 
[3]. However, stimulants suffer from drawbacks of reduced appetite, 
delayed onset of sleep and also the risk of misuse and abuse, thus 
reducing patient compliance. 
Atomoxetine (ATX) a non-stimulant has come to the forefront for the 
treatment of ADHD due to its high water solubility, favourable 
dissolution and intestinal permeability characteristics (BCS Class I) 
because of which it shows rapid absorption on oral administration. 
ATX is the first non-stimulant approved by the US-FDA and is an 
effective alternative to stimulants, especially for patients who have 
comorbidities that contraindicate their use. However, metabolism of 
ATX is governed by the genetic polymorphism of the enzyme 
CYP2D6. This enzyme can lead to higher first-pass metabolism in the 
case of extensive metabolizer of this drug and thus reduce the 
absolute oral bioavailability of ATX [4].  
The management of ADHD involves use of immediate release, 
extended release, and osmotic release oral dosage forms in addition 
to transdermal patch; however, the onset of action is longer for a 
drug delivered by the oral route. Also, because of constraints of 
blood-brain barrier time required to achieve effective concentration 
at site of action i.e. the brain is greater. Expression of efflux 
transporters in tissue compartments like the gastrointestinal tract 
and brain capillary endothelial cells limits the oral absorption and 
central nervous system entry (CNS) of many drugs[5]. Hence, 
alternative routes of administration are explored. The intranasal 
administration appears to be one such non-invasive and convenient 
route to target therapeutic moieties rapidly to the CNS [6, 8]. To 
state a few, the nasal route offers advantages of fast absorption of 
drug, circumventing first-pass metabolism and enhanced 
bioavailability at lower doses [9, 10]. Even in case of the intranasal 
route, the diffusion of drugs from the blood into the brain depends 
mainly upon the ability of the biologically active molecule to cross 
lipid membranes. Furthermore, in case of hydrophilic drugs, to 
achieve therapeutic concentrations by overcoming the blood-brain 
barrier is a challenging task. 
Hence, various strategies are in progress to deliver drugs 
intranasally into the brain which includes lipophilic analogues, 
prodrugs, microspheres, nano particles, liposomes, etc. [11]. Such 
targeted nose-to-brain drug delivery systems increase the 
therapeutic efficacy of CNS-acting drugs thereby reducing any 
systemic side effects as well. 
Liposomes have the advantages of being biodegradable, easy to scale 
up, greater specificity towards cells or tissue, protect drug degradation 
from nasal enzymes and thus make it a suitable colloidal carrier for 
intranasal delivery of the drug by allowing better access across the 
BBB compared to other carriers [12, 13]. However, the limitations 
posed by intranasal route can be slow diffusion of most drugs, and a 
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limited volume accommodated by the nasal cavity (150 μl/nostril) due 
to which the excess formulation will drain into the pharynx and be 
swallowed [14]. The addition of mucoadhesive agent is reported to 
enhance retention of formulation in the nasal cavity. 
Dhuria et al. and many others have demonstrated that inclusion of a 
short-acting vasoconstrictor in nasal formulations to enhance 
intranasal drug targeting to multiple brain area while significantly 
reducing systemic absorption [15]. This may hold relevance for the 
treatment of various neurological disorders. Highlighting the above 
aspects, the work undertaken relates to biopharmaceutical 
evaluation of ATX-Lipo for brain targeting when administered 
intranasally. Furthermore, the objective of the study was to evaluate 
brain uptake efficiency in the presence of vasoconstrictor 
(phenylephrine) in ATX liposomes. 
MATERIALS AND METHODS 
Materials and reagents 
ATX pure powder was obtained as a gift sample from Panchsheel 
Organics Ltd. (Mumbai, India). Phospholipon 90G was a gift sample 
from Lipoid, Germany and HPMC K4M as a gift sample from 
Colorcon, Mumbai. Chloroform AR, Disodium hydrogen 
orthophosphate AR, Potassium dihydrogen orthophosphate AR, 
Sodium chloride AR were purchased from S. D. Fine Chem. Ltd, India. 
Filtered distilled water was used throughout the study. All other 
chemicals and solvents were of analytical reagent grade and used as 
received without any further purification. 
Animals 
Animal experiments were carried out in accordance with the 
guidelines of the institutional ethics committee (Radiation Medicine 
Centre, Bhabha Atomic Research Centre, and Mumbai). Female 
Sprague Dawley rats are having a body weight in the range of 250–
300 g were used for the study. The animals were housed at a 
temperature of 22±3 °C and 65% relative humidity. Throughout the 
experiments, the animals were fed with a standard rat diet and were 
provided with clean drinking water ad libitum. 
Methods 
Preparation and characterization of ATX liposomes 
The liposomes of ATX were prepared by adapting the procedure 
described by Rania, M et. al for the lipid film hydration method [16]. 
Briefly a mixture of phospholipid, Phospholipon 90G and cholesterol 
in a molar ratio of 4:1 were dissolved in chloroform in a 100 ml 
round bottom flask. The solvent mixture was then evaporated in 
rotavapor apparatus (Superfit, India) at 40 °C (pressure 400-600 
mmHg) until a dry film was formed on the inner circumference of 
the round bottom flask. The dry film thus formed was hydrated with 
phosphate buffer saline (PBS) (pH= 7.4) containing drug (5 mg/ml) at 
60 °C. The dispersion was hand shaken and vortex mixed on 
cyclomixer (Remi, Mumbai) to get a homogenous mixture of ATX-Lipo. 
The mucoadhesive liposomes of ATX were formulated by adding 
required volume of the polymer solution of HPMC K4M (0.5% w/v) to 
the final volume of hydration medium to get ATX-Muco Lipo. To this 
liposomal suspension of ATX-Muco Lipo required a volume of 0.05% 
PHE solution was added to get ATX+PHE-Muco Lipo. The particle size 
distribution of the liposomes was evaluated by Dynamic light 
scattering spectroscopy (DLS) using Zetasizer Nano ZS (Malvern, U. 
K.). ATX-Lipo samples were further diluted with 0.45μ filtered distilled 
water to ensure that light scattering intensity was within instrument’s 
sensitivity range. These samples were placed in transparent 
polystyrene cuvettes (1 cm2) and loaded in thermo stated chamber. 
Light scattering was monitored at an angle of 173 ° to the incident 
beam, and all measurements were made in duplicates at 25 °C.  
The zeta potential of liposomal samples was measured by Laser 
Doppler velocimetry using Zetasizer Nano ZS at 25 °C (Malvern, U. 
K.). The zeta potential of a liposome preparation can help to predict 
the fate of the liposomes in vivo. Samples diluted 1 in 10 with filtered 
distilled water were placed in a disposable capillary cell and loaded 
in the thermo stated chamber. The scattered light detected from 
samples while a zeta potential measurement is made at the forward 
angle of 12 ° and all measurements were made in duplicates at 25 °C.  
The entrapment efficiency of ATX in liposomes was determined 
indirectly.  
Briefly, the formulated ATX liposomes were separated from un-
entrapped ATX by ultra-centrifugation at 80,000 rpm for 60 min at 4 
°C using Optima Max XP ultracentrifuge (Beckman Coulter, USA). 
The collected supernatant after suitable dilution with PBS pH 7.4 
was quantified by validated UV spectroscopy method at 270 nm. The 
ATX entrapment efficiency (EE) of liposomes was calculated as 
indicated below:  
%Entrapment efficiency 
=
Total amount of ATX loaded − Free ATX in supernatant
Total amount of ATX loaded
× 100 
Mucoadhesion potential was determined by modified pan balance 
fabricated in the laboratory [17]. The mucoadhesive force was 
calculated using the equation, F= W*g/a where, F= Mucoadhesion 
force (dynes/cm2), W= minimum weight in grams required to break 
the mucoadhesive bond, g= acceleration due to gravity (cm/s2) and 
a= surface area of the slide onto which the formulation was applied. 
Pharmacokinetic study 
The protocol for animal experimentation was approved by BARC 
Animal Ethics Committee (Protocol no: BAEC/13/15). The study was 
done in collaboration with Radiation Medicine Centre, Tata 
Memorial Hospital, Parel, and Mumbai. 
Preparation of technetium-tagged formulations 
ATX-Lipo, ATX-Muco Lipo, ATX+PHE-Muco Lipo and ATX solution 
preparations were tagged with radionuclide 99mTc by the direct 
labeling method [18]. To 1.0 ml of ATX liposomal formulations (5 
mg/ml) at pH=6, 100 μl of stannous chloride (1 mg/ml in 0.01N HCl) 
was added. Likewise, 1.0 ml of ATX solution prepared in saline was 
mixed with 50 μl of above stannous chloride solution. These sample 
mixtures of ATX liposomal formulations and ATX drug solution were 
shaken well and incubated for 10 min at room temperature, 
followed by addition of 1 ml of sterile 99mTc-pertechnate (75-400 
MBq) and the resultant reaction mixtures were again incubated for 
20 min at room temperature. 
The radiochemical purity of 99mTc tagged ATX formulations was 
determined by ascending instant TLC using silica gel coated 
aluminium backed sheets and acetone as the mobile phase. The 
99mTc tagged formulation complex and the 99mTc tagged drug 
complex remain at the point of the spots while free technetium 
moves towards the solvent front. 
The radiolabeling efficiency was calculated using equation given 
below:  
% Labeling efficiency 
=
Total counts − Counts of free Technetium
Total counts
× 100 
The effects of incubation time and stannous chloride concentration 
on radiolabeling efficiency were evaluated to achieve optimum 
conditions. 
The stability of the 99mTc tagged ATX formulations and drug 
complexes were also assessed at 37±2 oC up to 3 h. The optimized, 
stable 99mTc tagged formulations of ATX were used for bio 
distribution study in rats. 
Bio-distribution studies 
Female Sprague Dawley rats weighing between 200-250g were 
selected for the study. The 99mTc tagged complexes of 99mTc-ATX-
Lipo, 99mTc-ATX-Muco Lipo, and 99mTc-ATX+PHE Muco Lipo were 
administered intranasally. Similarly 99mTc-ATX-Lipo and 99mTc-ATX 
solution were injected through leg vein of Sprague Dawley rats. The 
administration and dosing details of the study protocol have been 
stated in table 1. Prior to nasal and intravenous administration of 
the formulations, the rats were anaesthetized using 50 mg/kg 
ketamine intramuscular injection. The formulations were instilled 
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into the nostrils with the help of micropipette (10-100μl) attached to 
a low-density polyethylene tube having 0.1 mm internal diameter at 
the delivery site. The rats were placed in supine position with a head 
angle of 90 ° while dosing and even after dosing for 1 min in order to 
prevent drainage of the dose. Rats were sacrificed at predetermined 
time intervals, and blood was collected using cardiac puncture. 
Subsequently, different organs including brain were isolated and 
99mTc radioactivity associated with each of them was counted using 
well-type gamma counter and percent uptake was calculated using 




 Radioactivity counts in an organ − Background count of instrument 
Total radioactivity counts in the body of rat
 × 100  
 
Unit of measurement: counts per second (cps) 
 
Table 1: Study details of bio distribution study 
Formulation Administration Volume Dose Euthanasia time points* (min) 
99mTc ATX Liposomes Intranasal 50 μl per nostril 125 μci/100 μl+0.125 mg atomoxetine 10, 30, 60, 180 
99mTc ATX Liposomes Intravenous 100 μl 125 μci/100 μl+0.125 mg atomoxetine 10, 30, 60, 180 
* n=3/time point 
 
To evaluate the brain-targeting efficiency, two indexes drug 
targeting efficiency (DTE %) and nose-to-brain direct transport 
percentage (DTP %) of ATX were determined. DTE (%) represents 
time average partitioning ratio, as derived from Equation (1). Direct 
transport percentage which defines nose-brain direct transport 
(DTP, %) was also calculated which is shown in equation (2). 
DTE% =  
(AUC brain/AUC blood) i. n
(AUC brain/AUC blood) i. v.
 × 100 (1) 
  
DTP % = (Bi. n −  Bx Bi. n⁄ )  × 100 (2) 
Where, Bx= (Bi. v/Pi. v) x Pi. n x Bx 
Bx is the AUC brain fraction contributed by systemic circulation 
through the BBB following intranasal administration, Bi. v is the AUC0–
180 (brain) following intravenous administration, Pi. v. is the AUC0–180 
(blood) following intravenous administration, Bi. n is the AUC0–180 
(brain) following intranasal administration, Pi. n. is the AUC0–180 (blood) 
following intranasal administration, AUC: Area under the curve. DTP 
(%) and DTE (%) were calculated using tissue/organ distribution data 
following intranasal and intravenous administrations [19]. 
Gamma scintigraphy imaging 
Sprague Dawley rats were selected for the study. The 99mTc tagged 
complexes of 99mTc-ATX-Sol and 99mTc-ATX+PHE Muco Lipo were 
administered i. n. (50 μl in each nostril) at a dose of 2 mg/kg body 
weight and kept for 30 min. The rats were held back in slanted 
position during nasal administration of the formulations. The rats 
were then anaesthetized using an intraperitoneal injection of ketamine 
and xylazine (20 mg/kg body weight) 10 min before imaging. The rat 
was fixed on a board in posterior-anterior position, and imaging was 
performed using e-Cam Dual Sign, Siemens gamma camera.  
Statistical analysis 
All data are reported as mean±SD and the difference between the 
groups was tested using Student’s t-test at the level of P<0.05. 
Pharmacokinetic parameters like AUC were calculated using 
Microsoft Excel software. 
RESULTS AND DISCUSSION 
Formulation development and characterization 
Liposomes can be prepared by a number of methods which includes 
ether injection method, handshaking method (Lipid film hydration 
technique), reverse phase evaporation technique, transmembrane 
pH gradient method. For the preparation of ATX loaded liposomes 
only lipid film hydration and ether injection were attempted, the 
results of which are depicted in table 2. 
The formed liposomal dispersion was homogeneous, and opaque, 
white in colour and all were stable for 24 h. It was also observed that 
the liposomes prepared with saturated lipid (PL 90H) and 
cholesterol in molar ratio 2:1 showed larger particle size compared 
to unsaturated lipids (PL 90G, S-100 and EPC). The entrapment 
efficiency was found to be low. It could be due to saturated nature of 
lipid, i.e. PL 90H having lipophilic nature which could possibly be 
competing with hydrophilic ATX in the lipid bilayer and reducing the 
entrapment of ATX. Glavas-Dodov et al. have reported similar 
observations for 5-flourouracil [20]. 
  
Table 2: Entrapment efficiency, particle size, polydispersity index (PI) and zeta potential of ATX loaded liposomes (n=3) 










1 PL 90H: CH 50 mg LFH 2:1 10.29±1.64 7854.00 1.00 7.39 
2 S-100:CH 50 mg LFH 1:1 39.13±3.50 315.10 0.43 28.40 
3 S-100:CH 50 mg LFH 2:1 54.89±4.72 445.75 0.52 35.00 
4 S-100:CH 50 mg Ether 2:1 36.25±4.63 661.20 0.64 14.70 
5 S-100:CH 50 mg LFH 3:1 61.00±2.83 394.30 0.8 40.90 
6 EPC: CH 50 mg LFH 1:1 45.50±3.96 591.85 0.58 23.00 
7 EPC: CH 50 mg LFH 2:1 46.26±4.23 351.00 0.58 22.30 
8 EPC: CH 50 mg LFH 3:1 51.16±4.37 345.65 0.55 28.10 
9 PL 90G: CH 50 mg LFH 1:1 46.25±0.71 413.45 0.40 24.00 
10 PL 90G: CH 50 mg LFH 2:1 53.57±1.27 484.60 0.30 34.15 
11 PL 90G: CH 50 mg Ether 2:1 37.00±3.68 322.60 0.65 15.10 
12 PL 90G: CH 50 mg LFH 3:1 62.00±3.22 531.65 0.28 36.70 
13 PL 90G: CH 50 mg LFH 2:3 27.80±0.85 884.05 0.61 25.55 
14 PL 90G: CH 75 mg LFH 4:1 78.31±1.85 404.35 0.41 40.65 
PC: Phosphatidylcholine, MA: Membrane additive, LFH: Lipid Film Hydration method, Ether: Ether injection method, PL 90H: Hydrogenated 
Phospholipon 90H, PL 90G: Phospholipon 90G, EPC: Egg phosphatidylcholine, CH = Cholesterol. 
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It was also observed that all liposomes prepared with unsaturated 
phospholipids allowed better entrapment of drug in the bilayer 
due to the kinks formed by cis-trans conformational changes of 
unsaturated lipids. As the molar ratio of phospholipids, drug 
entrapment increased with increase in particle size and PDI of 
liposomes. Liposomes prepared by adapting ether injection 
method resulted in only 37.00±3.68% entrapment of ATX as 
compared to liposomes prepared by lipid film hydration i.e. 
53.57±1.27%.  
Liposomes fabricated from either injection are mostly large 
unilamellar vesicles (LUV). Large unilamellar vesicles contain less 
bilayer compared to multilamellar vesicles and hence affect the 
entrapment efficiency of ATX loaded liposomes [21].  
 
Table 3: Characterization parameters of optimized ATX liposomes* 
Formulation Particle size (nm) Zeta potential (mV) Percent entrapment efficiency 
ATX-Lipo 404.35±1.86 +40.65±0.89 78.31±1.85 
ATX-Muco Lipo 510.50±1.22 +37.80±1.98 76.54±2.14 
*Parameters are derived using mean±SD, n=3 
 
The particle size range of 404.35±1.86 nm and 510.50±1.22 nm and 
PDI of 0.310±0.06 and 0.257±0.01 for ATX-Lipo and ATX-Muco Lipo 
respectively indicated that the liposomes approached a mono-
dispersed stable drug delivery system. The zeta potential of ATX-
Lipo and ATX-Muco Lipo was found to be+40.65±0.89 mV 
and+37.80±1.98 mV respectively. The acquired values of higher 
positive charge could be attributed to surface deposition of the drug 
which is cationically charged at pH value below 9 (since pKa is 
10.13) resulting in greater colloidal stability due to higher repulsion 
between particles [22, 23]. The optimized ratio of Phospholipon 90G 
and cholesterol (4:1) used for the formulation of liposomes gave 
good entrapment efficiencies of 78.31±1.85 % and 76.54±2.14 % for 
ATX-Lipo and ATX-Muco Lipo respectively. 
From the results of the preliminary screening, as shown in table 2, 
the suitable phospholipid and membrane additive for encapsulation 
of ATX was Phospholipon 90G and Cholesterol respectively. Lipid 
film hydration technique described by Rania M et al. was adapted for 
encapsulation of ATX in liposomes. As it has been reported that 
varying the molar ratio of phospholipid: cholesterol affects particle 
size, drug entrapment efficiency and zeta potential, hence in the 
present study too ATX liposomes were optimized by changing these 
variables.  
ATX liposomal formulations were thus prepared using lipids 
Phospholipon-90G and cholesterol in a fixed ratio of 4:1. HPMC K4M 
(0.5% w/w) was used as the mucoadhesive polymer, and 
Phenylephrine (PHE) (0.05% w/v) was added as a vasoconstrictor 
in ATX liposomal formulations to obtain ATX-Muco Lipo and 
ATX+PHE-Muco Lipo respectively. The formulated ATX-Lipo and 
ATX-Muco Lipo were then characterized for physicochemical 
parameters as depicted in table 3. 
Pharmacokinetic evaluation 
ATX-Lipo, ATX-Muco Lipo and ATX+PHE-Muco Lipo were 
effectively tagged with 99mTc and optimized for maximum 
radiolabeling efficiency and stability. Radiochemical purity 
achieved was 96.22% for ATX-Lipo at the end of 180 min (180 min 
was chosen for stability study of the radiolabeled formulations 
since it was the last time point for the sacrifice of rats). The 
optimal SnCl2 concentration was found to be 100 μl (1 mg/ml) for 
ATX liposomal formulations with an incubation time of 20 min. 
Thus, the radiolabeled formulations were found suitable for the 
pharmacokinetic study of ATX in rats. 
Bio distribution studies of 99mTc formulations following i. n. 
administration (ATX-Lipo, ATX-Muco Lipo and ATX+PHE-Muco 
Lipo) and i. v. administration (ATX-Lipo) on Sprague-Dawley rats 
were performed, and the radioactivity was estimated at different 
time intervals up to 180 min which is shown in table 4. 
The brain/blood ratios of the drug at all sampling time points for 
different formulations are graphically represented in fig. 1. The 
pharmacokinetic parameters were calculated from fig. 2 and 3 and 
were recorded in table 5. 
 
 
Fig. 1: Brain tissue-to-plasma atomoxetine concentration ratios 
as a function of time following intranasal and intravenous 
liposomes administration respectively in rats. The values 
represent mean±SD of three animals 
  
Table 4: Compartmental distribution 99mTc-ATX solution (intravenous), 99mTc-ATX Lipo (intranasal), 99mTc-ATX Muco Lipo (intranasal), 
99mTc-ATX+PHE Lipo (intranasal), 99mTc-ATX+PHE Muco Lipo (intranasal and 99mTc-ATX Lipo (intravenous) at different time intervals in 
normal Sprague Dawley rats (n=3)* 
Formulation and route of administration Organ 10 min 30 min 60 min 180 min 
ATX Lipo i. v. Blood 19.76±0.074 10.26±0.085 6.4±0.040 3.38±0.036 
Brain 0.0965±0.24 0.0317±0.012 0.066±0.063 0.0131±0.14 
ATX Lipo i. n. Blood 0.408±0.094 0.154±0.032 0.123±0.18 0.281±0.082 
Brain 0 0.0248±0.056 0.017±0.04 0.01±0.09 
ATX Muco Lipo i. n. Blood 0.169±0.010 0.09±0.09 0.141±0.02 0.141±0.03 
Brain 0.065±0.35 0.0565±0.057 0.109±0.049 0.039±0.42 
ATX+PHE Muco Lipo i. n. Blood 0.023±0.006 0.455±0.033 0.013±0.058 0.291±0.011 
Brain 0.025±0.014 0.151±0.091 0 0.048±0.042 
*The rats were administered with approximately 5 mCi 99mTc-atomoxetine and the radioactivity was measured in percentage per gram of tissue of 
the administered dose. Each value is the mean±SD. 
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Fig. 2: Blood concentrations vs. time (min) plot following 
intranasal and intravenous administrations of 99mTc-
atomoxetine formulations. The values represent mean±SD of 
three animals, p<0.05 
 
Fig. 3: Brain concentrations vs. time (min) plot following 
intranasal and intravenous administrations of 99mTc-
atomoxetine formulations. The values represent mean±SD of 
three animals, p<0.05
 
Table 5: Pharmacokinetic parameters of 99mTc labelled ATX formulations and ATX solution* 
Formulation Organ/Tissue C max (%) t max(min) AUC0-180 min (min %/g) 
ATX-Lipo i. v Blood 19.76±0.24 10 300.2±0.45 
Brain 0.0965±0.247 10 1.282±0.04 
ATX-Lipo i. n Blood 0.408±0.094 10 5.62±0.16 
Brain 0.0248±0.566 30 0.627±0.02 
ATX-Muco Lipo i. n Blood 0.169±0.01 10 2.59±0.15 
Brain 0.109±0.049 60 8.88±0.08 
ATX+PHE Muco Lipo i. n Blood 0.455±0.033 30 7.02±0.05 
Brain 0.151±0.091 30 2.26±0.07 
The rats were administered with approximately 5 mCi 99mTc-atomoxetine and the radioactivity was m, * Parameters are derived using mean±SD, n=3 
 
The pharmacokinetic studies revealed that the maximum 
concentrations (Cmax) of the drug in the brain and blood after i. n. 
and i. v. administration in rats were attained at different tmax 
values. Considering the concentration of drug achieved in the 
brain at a particular time interval, in the case of intranasal ATX-
Lipo a lower Cmax value (0.0248) was attained at a tmax of 30 min 
whereas the Cmax (0.109) for intranasal ATX-Muco Lipo was 
achieved at tmax of 60 min. 
The lower Cmax in brain for intranasal ATX-Lipo may be because of 
reduced residence time of the formulation due to nasolacrimal 
drainage. The observed higher Cmax value for intranasal ATX-Muco 
Lipo (0.109) at 60 min could be attributed to the viscous nature and 
crosslinking properties of the mucoadhesive polymer incorporated 
in the liposomal formulation. A similar observation has been 
reported by Ugwoke, M. et al. for nasal mucoadhesive delivery of 
Apomorphine [24] as a powder dosage form. 
The highest Cmax value in the brain (0.151) was achieved at 30 min 
when ATX+PHE-Muco Lipo was administered intranasally. PHE a 
vasoconstrictor is clinically known to be given in conjunction with 
local anaesthetics to prevent wash away of local anaesthetic from 
the site of action thus prolonging its effect at that site. The similar 
effect would be attributed when ATX+PHE-Muco Lipo was 
administered. Dhuria et al. have also demonstrated the higher brain 
uptake of intranasal therapeutic neuropeptides when phenylephrine 
was incorporated as a vasoconstrictor in their formulation [15]. 
The increased concentration or activity in blood seen for ATX+PHE-
Muco Lipo even in the presence of vasoconstrictor phenylephrine is 
unusual as seen in table 5. In a study done by Charlton et al. when 
ephedrine was co-administered as a vasoconstrictor along with the 
drug containing nasal formulation, higher drug blood concentrations 
were observed [25]. However, in other similar studies [26, 27] it was 
reported that vasoconstrictors were applied before initiating drug 
administration instead of co-administering with the nasal 
formulation. This indicated that in the present study application of 
the vasoconstrictor PHE prior to intranasal administration of ATX 
liposomal formulation instead of co-administration might have 
increased the probability of greater transport to the brain. 
From, table 5 a significantly higher brain AUC was observed for 
intranasal ATX-Muco Lipo (8.88 min %/g) and intranasal ATX+PHE-
Muco Lipo (2.26 min %/g) when compared with intravenous ATX-
Lipo(1.28 min %/g) indicating the efficiency of the liposomes for 
brain targeting. 
The BBR of 0.161, 1.255, 0.331, 0.003 for ATX-Lipo (i. n.), ATX-Muco 
Lipo (i. n.) ATX+PHE-Muco Lipo (i. n.), ATX-Lipo (i. v.) respectively at 
30 min indicate greater transport of drug to the brain after 
intranasal administration of liposomal formulations compared to 
intravenous administration of liposomes which is represented in 
fig.1. This could be indicative of direct transport of the liposomes 
bypassing the blood brain barrier due to a direct connection 
between the nose and brain because of the olfactory region present 
in the nasal cavity [28, 29]. 
The drug (ATX) targeting efficiency (DTE, %) and brain drug (ATX) 
direct transport percentage (DTP, %) were also calculated for 
nasally administered formulations from the pharmacokinetic data 
depicted in table 4. As shown in table 6 amongst the nasally 
administered formulations, ATX-Muco Lipo and ATX+PHE-Muco 
Lipo formulations showed greater DTE (%) and DTP (%) values 
followed by ATX-Lipo. Five-fold higher DTE (%) and three-fold 
higher DTE (%) for ATX-Muco Lipo and ATX+PHE-Muco Lipo 
respectively compared to ATX-Lipo demonstrated the significance of 
the mucoadhesive liposomal formulation. Similar studies have 
reported such results for nose-to-brain targeted intranasal 
mucoadhesive micro emulsion drug delivery systems [9, 30]. 
On application of Student’s t-test, no statistically significant 
difference was found between intranasal and intravenous routes of 
administration. Hence, in the present study to obtain statistically 
significant results there was a need for extensive animal studies. 
However, within the limits of the experimental design above results 
were obtained. 
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Table 6: Drug targeting efficiency and Direct transport percentage* derived following intranasal administration of 99mTc-ATX Lipo (intranasal), 
99mTc-ATX Muco Lipo (intranasal), 99mTc-ATX+PHE Lipo (intranasal), 99mTc-ATX+PHE Muco Lipo (intranasal) formulations 
Formulation and route of administration DTE % DTP % 
ATX-Lipo i. n. 52.13±2.34 98.08±0.16 
ATX Muco-Lipo i. n. 251.41±3.05 99.60±0.11 
ATX+PHE-Muco Lipo i. n. 182.21±4.21 99.45±0.32 
* Parameters are derived using mean±SD. 
 
In order to visualize brain uptake following intranasal 
administration of 99mTc tagged ATX solution and ATX-Lipo 
formulation gamma camera was used. The use of gamma ray 
emitting radionuclide 99mTc helped to perform imaging studies to 
complement the information obtained from tissue distribution 
experiments. fig. 4 and 5 depict the gamma scintigraphic images for 
intranasal ATX solution and intranasal ATX+PHE Muco Lipo 
respectively at 30 min post administration in rats. This was 
consistent with the results obtained from fig. 1 and table 5. 
From fig. 4 and 5 it was observed that most of the radiolabeled intranasal 
drug solution and liposomal formulation appeared in the stomach of rat. 
Similar results were also reported by Patel et al. for intranasal brain 
targeted risperidone solid lipid nano particles [31]. This is also 
supported by the graphical depiction of the bio distribution of the 
radiolabeled drug in various organs of rat in fig. 6 and 7 after intranasal 
and intravenous administration of formulation respectively. However, a 
considerable amount of drug was seen in the brain for intranasal 
ATX+PHE Muco Lipo as compared to intranasal ATX solution at 30 min 
post administration. 
 
Fig. 4: ATX solution (intranasal) 
 
 
Fig. 5: ATX+PHE muco lipo (intranasal) 
 
Fig. 6: Bio distribution of (A) ATX-Lipo (intravenous) and (B) 
ATX–Muco Lipo (intranasal) after 30 min. The values represent 
mean±SD of three animals, p<0.05 
 
 
Fig. 7: Biodistribution of (A) ATX-Lipo (intravenous) and (B) 
ATX+PHE-Muco Lipo (intranasal) after 30 min. The values 
represent mean±SD of three animals, p<0.05 
 
CONCLUSION 
In the present investigation, the utility of liposomes as a carrier for 
nasal delivery of ATX was studied. All formulations were 
successfully formulated, characterized and found suitable for 
intranasal administration. The preliminary results of this 
investigation along with the in vivo studies demonstrated the 
potential delivery of ATX to brain via a nasal route from 
formulations containing mucoadhesive polymer HPMC and 
vasoconstrictor phenylephrine i.e. ATX-Muco Lipo and ATX+PHE-
Muco Lipo. It also demonstrates the existence of nose-to-brain 
transport of ATX as evident through the gamma scintigraphy results.  
However, further detailed animal experimentation with a greater 
number of animals being sacrificed at more time points is warranted 
in order to obtain statistically significant results. 
ACKNOWLEDGEMENT 
Authors are thankful to University Grants Commission, India for 
providing financial support for carrying out this investigation. 
Shinde et al. 
Int J Pharm Pharm Sci, Vol 8, Issue 3, 286-292 
 
292 
Authors are also thankful to Radiation Medicine Centre, Tata 
Memorial Hospital, Parel, Mumbai for providing all facilities and 
permitting us to carry out experimental work. 
CONFLICT OF INTERESTS  
Declared none 
REFERENCES 
1. Faraone SV, Sergeant J, Gillberg C, Biederman J. The worldwide 
prevalence of ADHD: is it an American condition? World 
Psychiatry 2003;2:104. 
2. Madaan V, Kinnan S, Daughton J, Kratochvil CJ. Innovations and 
recent trends in the treatment of ADHD; 2006. 
3. De Sousa A, Kalra G. Drug therapy of attention-deficit hyperactivity 
disorder: current trends. Mens Sana Monograph 2012;10:45. 
4. Sauer JM, Ring BJ, Witcher JW. Clinical pharmacokinetics of 
atomoxetine. Clin Pharmacokinet 2005;44:571-90. 
5. Löscher W, Potschka H. Blood-brain barrier active efflux 
transporters: ATP-binding cassette gene family. NeuroRx 
2005;2:86-98. 
6. Elshafeey AH, Bendas ER, Mohamed OH. The intranasal 
microemulsion of sildenafil citrate: in vitro evaluation and in 
vivo pharmacokinetic study in rabbits. AAPS PharmSciTech 
2009;10:361-7. 
7. Fazil M, Haque S, Kumar M, Baboota S, Sahni JK, Ali J. 
Development and evaluation of rivastigmine loaded chitosan 
nanoparticles for brain targeting. Eur J Pharm Sci 2012;47:6-15. 
8. Mahajan HS, Mahajan MS, Nerkar PP, Agrawal A. Nanoemulsion-
based intranasal drug delivery system of saquinavir mesylate for 
brain targeting. Drug Delivery 2014;2:148-54. 
9. Vyas TK, Babbar A, Sharma R, Singh S, Misra A. Intranasal 
mucoadhesive microemulsions of clonazepam: preliminary 
studies on brain targeting. J Pharm Sci 2006;95:570-80. 
10. Jogani VV, Shah PJ, Mishra P, Mishra AK, Misra AR. The 
intranasal mucoadhesive microemulsion of tacrine to improve 
brain targeting. Alzheimer Dis Assoc Disord 2008;22:116-24. 
11. Haque S, Sahni JK, Ali J, Baboota S. Development and evaluation 
of brain targeted intranasal alginate nanoparticles for 
treatment of depression. J Psychiatr Res 2014;48:1-12. 
12. Biju S, Talegaonkar S, Mishra P, Khar R. Vesicular systems: an 
overview. Indian J Pharm Sci 2006;68:141. 
13. Arumugam K, Subramanian G, Mallayasamy S, Averineni R, Reddy 
M, Udupa N. A study of rivastigmine liposomes for delivery into the 
brain through intranasal route. Acta Pharm 2008;58:287-97. 
14. Shinde LR, Jindal BA, Devarajan VP. Microemulsions and 
nanoemulsions for targeted drug delivery to the brain. Curr 
Nanosci 2011;7:119-33. 
15. Dhuria SV, Hanson LR, Frey WH. Novel vasoconstrictor 
formulation to enhance intranasal targeting of neuropeptide 
therapeutics to the central nervous system. J Pharmacol Exp 
Ther 2009;328:312-20. 
16. Hathout RM, Mansour S, Mortada ND, Guinedi AS. Liposomes as 
an ocular delivery system for acetazolamide: in vitro and in vivo 
studies. AAPS PharmSciTech 2007;8:1-12. 
17. Aher ND, Nair HA. Bilayered films based on novel polymer 
derivative for improved ocular therapy of gatifloxacin. Sci World 
J 2014. Doi.org/10.1155/2014/297603. [Article in Press] 
18. Saha GB. Physics and Radiobiology of Nuclear Medicine. 
Springer; 2010. 
19. Kumar M, Misra A, Mishra A, Mishra P, Pathak K. Mucoadhesive 
nanoemulsion-based intranasal drug delivery system of 
olanzapine for brain targeting. J Drug Targeting 2008;16:806-14. 
20. Glavas-Dodov M, Fredro-Kumbaradzi E, Goracinova K, 
Simonoska M, Calis S, Trajkovic-Jolevska S, et al. The effects of 
lyophilization on the stability of liposomes containing 5-FU. Int 
J Pharm 2005;291:79-86. 
21. Caddeo C, Teskač K, Sinico C, Kristl J. Effect of resveratrol 
incorporated in liposomes on proliferation and UV-B 
protection of cells. Int J Pharm 2008;363:183-91. 
22. Law S, Huang K, Chou V, Cherng J. Enhancement of nasal 
absorption of calcitonin loaded in liposomes. J Liposome Res 
2001;11:165-74. 
23. Laouini A, Jaafar-Maalej C, Sfar S, Charcosset C, Fessi H. 
Liposome preparation using a hollow fiber membrane 
contactor—Application to spironolactone encapsulation. Int J 
Pharm 2011;415:53-61. 
24. Ugwoke MI, Sam E, Van Den Mooter G, Verbeke N, Kinget R. 
Nasal mucoadhesive delivery systems of the antiparkinsonian 
drug, apomorphine: influence of drug-loading on in vitro and in 
vivo release in rabbits. Int J Pharm 1999;181:125-38. 
25. Charlton ST, Davis SS, Illum L. Evaluation of the effect of 
ephedrine on the transport of drugs from the nasal cavity to the 
systemic circulation and the central nervous system. J Drug 
Targeting 2007;15:370-7. 
26. Järvinen K, Urtti A. Duration and long-term efficacy of 
phenylephrine-induced reduction in the systemic absorption of 
ophthalmic timolol in rabbits. J Ocul Pharmacol Ther 
1992;8:91-8. 
27. Kyyrönen K, Urtti A. Effects of epinephrine pretreatment and 
solution pH on the ocular and systemic absorption of ocularly 
applied timolol in rabbits. J Pharm Sci 1990;79:688-91. 
28. Thakkar HP, Patel AA, Chauhan NP. The intranasal 
mucoadhesive microemulsion of mirtazapine: pharmacokinetic 
and pharmacodynamic studies. Asian J Pharm 2013;7:36. 
29. Patel MR, Patel RB, Bhatt KK, Patel BG, Gaikwad RV. 
Paliperidone microemulsion for nose-to-brain targeted drug 
delivery system: a pharmacodynamic and pharmacokinetic 
evaluation. Drug Delivery 2016;23:346-54. 
30. Vyas TK, Babbar A, Sharma R, Misra A. Intranasal 
mucoadhesive microemulsions of zolmitriptan: preliminary 
studies on brain-targeting. J Drug Targeting 2005;13:317-24. 
31. Patel S, Chauhan S, Soni H, Babbar A, Mathur R, Mishra A, et al. 
Brain targeting of risperidone-loaded solid lipid nanoparticles 
by the intranasal route. J Drug Targeting 2011;19:468-74. 
 
